Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 10/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179232 | 0.90 | PIK3CG (0.41) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL1685906 | 0.89 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| Dimethylamine SCHEMBL1685907 | 0.87 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| Azd-8418 SCHEMBL30795783 | 0.85 | PIK3CG (0.71) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| Azd-8418 SCHEMBL1178353 | 0.85 | PIK3CG (0.71) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL1178306 | 0.84 | NPC1 (0.52) | PIK3CGSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL1178249 | 0.79 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL1178769 | 0.78 | PIK3CG (0.43) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL2996048 | 0.78 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL1178192 | 0.78 | PIK3CG (0.69) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148372-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| EP-2303872-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-12-16 | — | — | US | claimed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | claimed |
| EP-2772492-B1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | ASTRAZENECA AB (SE) | 2016-08-17 | — | — | EP | disclosed |
| EP-2772492-B1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | ASTRAZENECA AB (SE) | 2016-08-17 | — | — | EP | disclosed |
| EP-2772492-A1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | AstraZeneca AB (SE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2772492-A1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | AstraZeneca AB (SE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2303872-B1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2303872-B1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2014-04-16 | — | — | EP | disclosed |
| US-8148372-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148372-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-7781434-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | PIK3CG 2627/4885PIK3CD 2609/4885PIK3CA 2283/4885 |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | GRM1, GRM3, GRIN1 | PIK3CG 2539/4885PIK3CD 2563/4885PIK3CA 2300/4885 |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | PIK3CG 2627/4885PIK3CD 2609/4885PIK3CA 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.